When I was diagnosed with stage 4 colorectal cancer, I did what a lot of people do — I went down the research rabbit hole. And somewhere between the PubMed abstracts and the late-night forum threads, I stumbled onto a world my oncologist had never mentioned: off-label medications for cancer.
It changed how I approached my treatment. And I think every cancer patient should at least know it exists.
What Are Off-Label and Repurposed Drugs?
An off-label medication is a drug that’s FDA-approved for one condition but used for another. This isn’t fringe medicine — it’s incredibly common. Doctors prescribe drugs off-label every day. Your oncologist has almost certainly done it.
Repurposed drugs for cancer treatment take this a step further: researchers have identified existing, often cheap medications — originally developed for completely different conditions — that show anticancer properties in lab studies, animal models, and sometimes clinical trials.
We’re talking about drugs that have been safely used by millions of people for decades. They have known safety profiles. They’re affordable. And some of them have genuinely promising data against various cancers.
Why Your Oncologist Probably Hasn’t Mentioned Them
This is the part that frustrated me the most. These drugs exist in peer-reviewed literature. The data is real. So why the silence?
A few reasons:
No financial incentive. Most repurposed drugs are generic. No pharmaceutical company is going to spend hundreds of millions on a clinical trial for a drug they can’t patent. Without large randomized controlled trials, oncologists don’t have the “gold standard” evidence they need to formally recommend them.
Liability concerns. Recommending something outside standard-of-care guidelines exposes doctors to risk. Even if the data looks promising, it’s safer professionally to stick to NCCN protocols.
They’re busy. Oncologists are managing enormous patient loads. Keeping up with repurposed drug research on top of everything else just isn’t realistic for most of them.
I don’t blame my doctors. But I do think the system leaves a gap that patients have to fill themselves.
What I Looked Into
I’m not going to list dosages here — that’s between you and your medical team, and context matters enormously. But I will share that some of the repurposed drugs I researched and discussed with my doctors include:
- Mebendazole — an antiparasitic with interesting preclinical data showing anti-tumor activity across several cancer types, including colorectal cancer
- Cimetidine — a common heartburn medication with studies suggesting immune-modulating effects
- Aspirin / NSAIDs — with a growing body of evidence around colorectal cancer specifically
- Statins — originally for cholesterol, now being studied for potential anticancer properties
- Metformin — a diabetes drug with epidemiological data suggesting lower cancer incidence
Each of these has a different level of evidence, different mechanisms, and different risk profiles. Some are more compelling than others. None of them are a replacement for standard treatment — they’re potential additions to it.
Self-Advocacy Is Not Optional
If there’s one thing cancer taught me, it’s that nobody will advocate for you the way you will. Your oncologist’s job is to give you the standard of care. Going beyond that — looking at what else might help, what the research says, what’s low-risk and potentially high-reward — that’s on you.
Read the studies. Ask questions. Bring information to your appointments. Find a doctor who will engage with you rather than dismiss you.
I built a ranked list of every repurposed medication I researched, organized by strength of evidence, in The CRC Roadmap. If you want the full breakdown — what I took, what I passed on, and why — you can find it at beat-crc.com.
Your treatment plan shouldn’t end where your oncologist’s protocol does.
— Aaron M.
Keep reading:
The CRC Roadmap 
Leave a comment